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Take home message: Thresholds to admit bronchiolitis patients to PICU have 
changed over the past decade with a major impact on costs and resource utilization. 
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ABSTRACT  
Bronchiolitis represents the most common cause for non-elective admission to 
pediatric intensive care units (ICUs).  
We assessed changes in admission rate, respiratory support, and outcomes of 
infants <24 months with bronchiolitis admitted to ICU between 2002 and 2014 in 
Australia and New Zealand.  
During the study period, bronchiolitis was responsible for 9,628 (27.6%) of 34,829 
non-elective ICU admissions. The estimated population-based ICU admission rate 
due to bronchiolitis increased by 11.76/100,000 each year (95%-CI 8.11-15.41). The 
proportion of bronchiolitis patients requiring intubation decreased from 36.8% in 
2002, to 10.8% in 2014 (adjusted OR 0.35; 0.27-0.46), whilst a dramatic increase in 
high-flow nasal cannula therapy use to 72.6% was observed (p<0.001). We observed 
a considerable variability in practice between units, with six-fold differences in risk-
adjusted intubation rates which were not explained by ICU type, size, nor major 
patient factors. Annual direct hospitalization costs due to severe bronchiolitis 
increased to over US$30 M in 2014. 
In conclusion, we observed increasing health care burden due to severe bronchiolitis, 
with a major change in practice in the management from invasive to non-invasive 
support suggesting thresholds to admit bronchiolitis patients to ICU have changed. 
Future studies should assess strategies for management of bronchiolitis outside 
ICUs. 
 
Abstract Word count: 199 
. 
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Keywords: infant; ventilation; bronchiolitis; intensive care; high-flow nasal cannulae 
 
Abbreviations: 
OR   Odd’s ratio 
PICU  Paediatric Intensive Care Unit 
PIM  Paediatric Index of Mortality 
IV  Invasive ventilation 
NIV  non-invasive ventilation 
CPAP  continuous positive airway pressure 
BIPAP biphasic positive airway pressure 
HFNC  high-flow nasal cannulae 
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Introduction 
 
Bronchiolitis is a common viral lower respiratory tract infection in infants 
characterized by acute small airway inflammation, and represents the leading cause 
for hospital admission during the first year of life[1]. In high income countries, 
approximately one out of eight infants hospitalized with bronchiolitis require 
admission to Intensive Care Units (ICU) for respiratory support as a result of 
progressive respiratory distress with respiratory failure and hypoxemia[2, 3]. Despite 
a general trend towards a reduction in hospital admissions overall, bronchiolitis-
related hospitalization costs have recently increased amounting to US$1.73 billion 
per year in the US[4]. In the past decades, pharmacological interventions have failed 
to show any benefit, and as a result, consensus guidelines emphasize supportive 
treatment options[2, 3, 5-8]. While invasive ventilation (IV) was traditionally 
considered the cornerstone of treatment for severe bronchiolitis in ICU, over recent 
years, an increasing number of single center studies have reported benefits 
associated with early use of non-invasive ventilation (NIV) and High-Flow Nasal 
Cannula (HFNC) therapy to reduce the need for intubation and IV in bronchiolitis[9-
13].  
 
The aims of this study were to describe the population-based admission rate and 
severity of bronchiolitis in infants in Australia and New Zealand admitted to intensive 
care, to determine risk factors for invasive ventilation, and to assess trends in 
admission rate, management, outcome and associated direct health care costs over 
a 13 year period from 2002-2014.  
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Methods (see as well Online Supplementary Material) 
 
A multicenter, binational, retrospective study of all patients reported to the Australian 
and New Zealand Paediatric Intensive Care (ANZPIC) Registry[14]. The study was 
approved by the Human Research and Ethics Committee (Mater Health Services 
HREC, Brisbane, Australia) including waiver of informed consent. The ANZPIC 
Registry prospectively records demographics, physiologic variables at admission, 
intensive care support, diagnoses and outcomes of PICU and general ICU 
admissions in children <16 years of age in Australia and New Zealand[14], and 
captures 92-94% of all pediatric ICU admissions.  
Inclusion and Exclusion Criteria: Infants aged <729 days and admitted with a 
diagnosis of bronchiolitis[8] and who were admitted to a pediatric ICU (PICU) or a 
general ICU in Australia or New Zealand between 1st January 2002 and 31st 
December 2014 were included. Elective admissions were excluded and infants with 
preexisting tracheostomies were excluded.  
Outcomes and definitions: The primary outcome was defined as the proportion of 
infants requiring intubation and invasive ventilation (IV). Non-invasive ventilation 
(NIV) was defined as continous positive airway pressure (CPAP) with or without 
pressure support delivered through a nasal mask, full-face mask, or a 
nasopharyngeal tube. Mechanical ventilation was defined as either IV and/or NIV.  
Since 2010, the ANZPIC registry has been prospectively recording the use of high-
flow nasal cannulae oxygen (HFNC) therapy. HFNC was defined as  > 1L/kg/min flow 
of a gas oxygen mixture through nasal cannula, and was coded separately from 
mechanical ventilation support [12, 13]. Data analyses were therefore separated into 
two periods: a period before widespread use of HFNC therapy (2002-2009) and a 
period post widespread introduction of HFNC therapy (2010-2014). With the 
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exception of one PICU, HFNC was not routinely used in the main PICUs and ICUs 
prior to 2010.  
Cost estimates methodology are provided in the Supplementary Material.  
 
Statistics: 
Data are presented as percentages and numbers or means with standard deviation. 
T-tests were used to compare subgroups. Population-based admission rate 
estimates were calculated. We assessed linear trends in respiratory support over the 
13-year period. In addition, trends during the 13-year study period were assessed by 
comparing risk-adjusted need for invasive ventilation. We constructed a multivariate 
prediction model for the need for invasive ventilation. For multivariable models, all 
significant predictors from the univariable analyses were used. We used a backward 
stepwise elimination procedure to eliminate non-significant predictors based on 
p>0.05.  
All PICUs in Australia and New Zealand contributed to the ANZPIC registry for the 
entire duration of the study period. The number of general ICUs contributing to the 
registry increased from 6 to 19 during the study period. In order to account for 
potential reporting bias, the following predefined subgroup analyses were performed: 
i) specialized pediatric ICUs (PICUs); ii) general (mixed adult and pediatric) ICUs; iii) 
pediatric and general ICUs that had been contributing for the entire length of the 
study period to the ANZPIC registry.  
Further details of risk prediction models are provided in the Supplementary Material. 
All analyses were conducted using Stata (version 12.1, Stata Corp, College Station, 
Texas, USA). P-values less than 0.05 were considered significant. 
 
 
Page 8 of 45European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 9
Results 
 
During the study period, Bronchiolitis was the most common cause of ICU admission, 
and was responsible for 9,628 (27.6%) of 34,829 non-elective admissions in infants 
below two years of age. 324 infants with tracheostomies in situ at time of admission 
were excluded. Prematurity (20 %), chronic respiratory conditions (10%) and 
congenital cardiac disease (7 %) were the most common underlying conditions 
(Table 1). During 2010 to 2014 (post widespread introduction of HFNC), 5670 infants 
were admitted with bronchiolitis in comparison to 3634 during 2002 to 2009 (Table 2). 
In recent years, infants with bronchiolitis admitted to ICU were older, less likely to 
retrieved, more likely to be admitted to a general ICU, and less likely to have 
underlying diseases (p<0.001). The average severity of disease as measured by 
PIM2 decreased significantly, and ICU and hospital LOS decreased accordingly. The 
crude mortality over the entire study period was 0.38% (35/9304). The re-calibrated 
PIM2 standardized mortality ratio declined from 1.53 (0.99-2.26) in 2002-2009 down 
to 0.54 (0.26-0.98) in 2010-2014. 
 
The annual number of infants with bronchiolitis admitted to ICU (including pediatric 
and general ICUs) increased from 383 cases in 2002 to 1528 cases in 2014 (Table 2, 
Figure 1). The total number of all non-elective ICU admissions per year during this 
time increased from 1933 to 4115. The estimated population-based age-standardised 
admission rate of bronchiolitis increased during the study period with an average 
annual increase of 11.76/100,000 infants <24 months (95%-CI 8.11 to 15.41). The 
change in admission rate was most pronounced in general ICUs, which took 40% of 
all bronchiolitis admissions requiring intensive care in 2014 (p<0.0001). The increase 
in admission was less marked when restricting analyses to PICUs (annual increase 
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5.80/100,000; 95%-CI 3.68 to 7.90), and when restricting to ICUs that had 
contributed to the registry for the entire study duration (6.21/100,000; 95%-CI 3.80 to 
8.63). The increase in bronchiolitis admission was higher compared to admissions 
due to any respiratory infection, and higher compared to all annual PICU admissions, 
which increased from 1933 to 4115 (Table 2). 
 
In 2002, 37% of patients with bronchiolitis were intubated/invasively ventilated, in 
comparison to only 11% in 2014 (p<0.001, Figure 2 and Supplementary Table 1). In 
view of the concomitant dramatic increase in bronchiolitis-related ICU admission 
rates, we calculated estimates of population-based intubation rates (Supplementary 
Table 2). Absolute intubation numbers and population-based intubation rates in 
infants with bronchiolitis did not decrease significantly during the study period 
(p>0.05). We observed a decrease in the proportion of intubations performed in ICU 
after the first hour of admission from from 66.2% (674/1018) in 2002-2009 to 43.6% 
(394/903) in 2010-2014. The time to intubation in infants that were not intubated 
within the first hour of admission did not change during the study period (p=0.840;  
Supplementary Figure 1). Over the same period, the length of mechanical ventilation 
(IV and/or NIV) decreased significantly from a mean duration of 109 hours to 69 
hours (average decrease 3.4 hours per mechanically ventilated patient per year; 
95%-CI 2.25 to 4.56). Following the introduction of HFNC therapy in most PICUs, the 
use of HFNC in infants with bronchiolitis increased during 2010-2014 to 72.6%, which 
was accompanied by a reduction in the use of NIV. The findings observed in the 
entire cohort were confirmed in subgroup analyses restricted to PICUs only, and to 
PICUs and ICUs that had contributed to the registry for the entire study duration 
(Figure 2 and Supplementary Table 1 and 2). 
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In multivariate analyses, age, interhospital transport, major chronic conditions, 
prematurity, and severity indicators such as low systolic blood pressure were 
identified as significant predictors for intubation (Table 3; AUC 0.76, 0.75-0.77). Each 
year was associated with a 0.9% decline in the risk of intubation (95% CI: 0.81-
1.00%). The overall adjusted odds for intubation decreased significantly from 
2002/2003 to 2014 (OR 0.35, 95%-CI 0.27-0.44, p<0.001) (Figure 3).  The model 
performed comparably when restricted to infants that were not intubated on arrival to 
PICU (Supplementary Table 3A). For children treated with HFNC, younger age, 
bronchopulmonary dysplasia, congenital heart defects, low blood pressure, and 
increased negative base excess were the main predictors of intubation (p<0.01, 
Supplementary Table 3B). 
 
When comparing the risk-adjusted rate of an infant with bronchiolitis receiving 
invasive ventilation, important differences between units were noted (Figure 4). When 
compared to an intercept-only mixed effects model, a model which controlled for year 
and patient risk factors (Table 3) demonstrated a 39.1% reduction in the variance of 
the random effect. This suggests that 60.9% of the variation in intubation rates were 
not explained by the case mix nor by time trends, and likely reflect underlying 
differences in unit-to-unit practice. Using the average risk profile for intubation, the 
probability a child with bronchiolitis being intubated varied from 6.9% to 36.7% across 
units.  
 
We assessed total direct hospitalization-related costs in infants requiring ICU 
admission, including ICU and ward costs. Although a reduction in LOS over the 
period of 2002-2014 occurred, the total annual costs increased from AU$11.4 M in 
2002 to $44.3 M in 2014 (Supplementary Table 4 and Figure 5). The total costs 
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related to bronchiolitis admitted to specialized PICUs increased from $10.7 M to 
$31.1 M over the same period.  
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Discussion 
 
This large binational study including over 9,000 critically ill infants with bronchiolitis 
demonstrates that severe bronchiolitis is responsible for a huge burden of disease, 
resulting in over US$30 M direct costs each year in Australia and New Zealand. 
Bronchiolitis has a major impact on ICU resource consumption, accounting for >25% 
of non-elective PICU admissions in infants. In the absence of high-grade evidence for 
treatment of bronchiolitis in ICU, we observed a dramatic increase in the number of 
children admitted to intensive care in Australia and New Zealand with bronchiolitis, 
concomitant with the increased use of HFNC therapy. In view of close to zero 
mortality in infants with severe bronchiolitis, these findings indicate an urgent need 
for future studies investigating whether a proportion of these patients may be safely 
managed outside the intensive care unit, hence reducing associated health-care 
costs. 
 
By estimating population-based ICU admission rates, we were able to document a 
major change in practice over the past decade, with a dramatic increase in ICU 
admissions in infants with bronchiolitis that are not requiring invasive ventilation. The 
increase observed in general ICUs may have been enhanced by reporting bias, as 
more general ICUs have contributed data to the study database over recent years. 
However, the findings were reproduced in subgroup analyses restricted to PICUs, 
and restricted to those centers that had provided data for the entire study duration. 
Infants with bronchiolitis admitted in recent years to ICU were less likely to have 
underlying comorbidities, older, and their predicted mortality was lower, suggesting 
changing thresholds for ICU admission. At the same time, we observed a 
considerable variability in practice between units, with over six-fold differences in 
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risk-adjusted intubation rates which was not explained by ICU type, size, nor major 
patient factors. Our findings support a recent northamerican study on bronchiolitis 
which observed >3.5-fold variation in the risk of intubation between PICUs, and a 
high variability in the proportion of patients exposed to other non-evidence based 
interventions[15]. While bronchiolitis hospital admission rates and length of stay have 
been proposed as benchmarks in the NHS Atlas of Variation in Healthcare 
(http://www.chimat.org.uk/variation), ICU resource use have not been investigated. 
Of note, the study period witnessed the implementation of rapid response teams and 
early warning tools (EWTs) in the major pediatric hospitals, followed by regional 
hospitals. While EWTs have been shown to predict the need for ICU admission, and 
reduce cardiopulmonary arrests in ward setting[16], to the best of our knowledge they 
have not been validated specifically for bronchiolitis. Indeed, infants with severe 
bronchiolitis commonly manifest tachycardia, tachypnea, and increased work of 
breathing, and may relatively rapidly trigger EWTs – with an unknown impact on 
health outcomes and resource utilization. 
Our data shows that this increase in ICU admission rates has been associated with a 
rapid expansion in costs, despite a reduction in LOS in intensive care and a shorter 
duration of ventilation. Our costs are comparable to a recent European study, which 
reported a four times higher cost for children requiring ICU compared to those treated 
on the ward (EUR €8061 versus €1834)[17]. 
 
Our study demonstrates that despite lack of larger trials on HFNC use in infants, 
HFNC therapy has become the most common support mode for critically ill infants 
with bronchiolitis in Australia and New Zealand recently, with over 70% of admissions 
in 2014 supported with HFNC. At the same time, while the proportion of admissions 
requiring intubation and IV dropped, we did not observe a significant reduction in the 
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absolute number of children requiring IV. Our observation parallels several single 
center studies reporting a drop in intubation rates in patients with severe bronchiolitis 
following the increased use of NIV and HFNC[10, 12, 13, 18-22], and suggests that 
these have led to a major change of practice in the absence of higher grade 
evidence. Recent large randomized trials in adults have demonstrated efficacy of 
HFNC therapy for acute hypoxemic respiratory failure[23, 24]. In the neonatal 
population, HFNC therapy was shown to be non-inferior to nasal CPAP[25, 26]. 
While the physiological effects of HFNC therapy, including provision of 4-5cm H2O 
CPAP, reduction in inspiratory work of breathing through provision of flows matching 
or greater than peak inspiratory flows, and washout of nasopharyngeal deadspace 
have been independently confirmed[27, 28], there is a lack of randomized-controlled 
trials to support either outcome benefit or cost benefit of HFNC therapy in the 
pediatric age group. A recent adult single center study has reported higher mortality 
in patients treated with HFNC that required delayed emergency intubation[29]. In our 
cohort, the increasing use of HFNC was not associated with a delay in intubations, 
and in fact the proportion of late intubations, mortality, length of mechanical 
ventilation, and length of ICU stay decreased. 
 
Advantages of HFNC therapy include an excellent safety profile, low equipment 
costs, easy application, and increased patient comfort compared to other forms of 
respiratory support. As a result, the application of HFNC therapy outside ICU settings 
has been increasingly tested, and single centre studies suggest safety, feasibility, 
and efficiency of such an approach[18], although the translation of this approach into 
better outcomes remains to be proven. Bronchiolitis is a relatively uniform disease 
with close to zero mortality, patients mostly demonstrate gradual rather than 
precipitous deterioration, and predictors can be used to stratify severity[30]. As a 
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result, this disease may in fact be optimally suited to design interventional trials 
aiming to reduce the number of intensive care admissions[31].  
 
We believe the results of this study have several implications for the design of further 
research on bronchiolitis. Firstly, they highlight an urgent need to validate early 
warning tools for bronchiolitis, as these may have a direct impact on intensive care 
admission rates. Secondly, improved markers of severity, including viral genomic 
load[32], may assist in optimizing risk stratification to target groups most likely to 
develop severe respiratory failure. Thirdly, the variation in respiratory support 
practice suggests a lack of standardized protocols[5, 8]. Fourthly, the dramatic 
change of practice seen in respiratory support modes warrants a PICU trial of HFNC 
therapy versus NIV versus low flow oxygen for infants and children with respiratory 
failure[24]. Finally, our data suggest that it is likely that a considerable proportion of 
intensive care patients may be good candidates to be considered for treatment 
outside ICU; whether HFNC therapy provides a cost benefit in such a setting has to 
be tested by large trials[31]. Importantly, trials on optimal respiratory support outside 
ICU may inform on the development and implementation of cost-effective 
interventions relevant at a global scale, with the potential to translate into mortality 
benefits in resource poor countries[33]. 
Several limitations of this study need to be considered. While we were not able to 
assess overall hospital admissions due to bronchiolitis, we captured every patient 
admitted to a general ICU or PICU in Australia and New Zealand providing data to 
the registry. Although bronchiolitis is well defined as a clinical entity[8], overlap with 
reactive airway diseases may lead to diagnostic challenges, potentially resulting in 
overdiagnosis of the disease. The use of HFNC was not prospectively captured prior 
to 2010, and we therefore can not comment on how frequently HFNC was used as a 
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respiratory support mode prior to 2010. Furthermore, we did not have access to 
detailed microbiological data, and extended nasopharyngeal virus polymerase-chain 
reaction tests were not consistently performed in centers throughout the study. 
Because the large majority of infants with bronchiolitis admitted to ICU did not 
receive intra-arterial monitoring on admission, we were unable to stratify by the 
degree of hypoxemia. Finally, FiO2/SpO2 ratios could not be used as the true FiO2 is 
unknown in HFNC or low flow oxygen therapy. In addition, we did not have access to 
pCO2 values measured on admission to ICU, however elevated pCO2 represent a 
common finding in bronchiolitis and may not indicate necessarily a need for 
intubation[34]. 
 
In conclusion, severe bronchiolitis remains responsible for a huge burden of disease. 
We observed a major change in practice in the management of severe bronchiolitis 
with dramatically increased early use of HFNC therapy despite the lack of high-grade 
evidence for treatment benefit in this age group. Our data suggests that thresholds to 
admit bronchiolitis patients to intensive care have reduced over the past decade with 
a major impact on healthcare-related costs and resource utilization in ICUs in 
Australia and New Zealand. International trials addressing the risk stratification and 
safe management of bronchiolitis outside intensive care settings are urgently 
warranted. 
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Figure legends 
Figure 1: Estimated population-based ICU admission rates due to bronchiolitis. 
ICU admission rates per 100,000 infants < 24 months and year are shown for A) all 
ICU admissions captured in the Australian and New Zealand Paediatric Intensive 
Care Registry; B) admissions to Pediatric Intensive Care Units (PICUs); C) 
admissions to general Intensive Care Units (ICUs); D) admissions to PICUs and 
ICUs that had contributed to the registry for the entire study duration 2002-2014. Red 
line: age 28days to <90 days; blue line: age neonates <28days; green line: 90 days 
to <1 year; purple line: 1 year to <2 years. 
 
Figure 2: Changes is respiratory support mode during the study period 2002 to 
2014 in infants admitted to ICU with bronchiolitis. Mechanical ventilation (green 
line) is defined as intubation (purple line: invasive ventilation) and/or non-invasive 
ventilation (blue line). High-flow nasal cannulae (HFNC) is shown in orange. 
Proportions of respiratory support mode used per patient (more than one modality 
allowed) are shown for A) all ICU admissions captured in the Australian and New 
Zealand Paediatric Intensive Care Registry; B) admissions to Pediatric Intensive 
Care Units (PICUs); C) admissions to general Intensive Care Units (ICUs); D) 
admissions to PICUs and ICUs that had contributed to the registry for the entire study 
duration 2002-2014.  
 
Figure 3: Adjusted risk for intubation/invasive ventilation in infants with 
bronchiolitis during the study period. Odds ratios are adjusted for age, 
interhospital transport, chronic respiratory and neurological conditions, prematurity, 
congenital heart disease, specific respiratory viruses, low systolic blood pressure, 
and are shown for A) all ICU admissions captured in the Australian and New Zealand 
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Paediatric Intensive Care Registry; B) admissions to Pediatric Intensive Care Units 
(PICUs); C) admissions to general Intensive Care Units (ICUs); D) admissions to 
PICUs and ICUs that had contributed to the registry for the entire study duration 
2002-2014.  
 
Figure 4. Comparison of the probability of an infant with bronchiolitis receiving 
invasive ventilation between different pediatric and general Intensive Care 
Units. (Area of bubble indicates relative admission numbers, purple bubbles indicate 
PICUs, red bubbles indicate general ICUs).  
 
Figure 5: Annual direct hospitalization cost (in AU$ 2014) due to severe 
bronchiolitis requiring ICU admission in Australia and New Zealand from 2002 
to 2014. Length of stay (LOS), and associated costs estimated by Independent 
Hospital Pricing Authority (IHPE) Efficient Price Determination are shown for 
Children`s hospitals and general hospital. 
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Table 1: Baseline and severity characteristics of patients with bronchiolitis 2002-2014. 
  Bronchiolitis 
  2002-2009 2010-2014 p 
Total N  3 634 (100%) 5 670 (100%)  
Age Median (IQR) [days] 91 (45-201) 139 (57-281) <0.001 
 Neonates <28 days  392 (10.8%) 463 (8.2%) <0.001 
 28d-90d 1 397 (38.4%) 1 680 (29.6%)  
 91d- 1 year  1 558 (42.9%) 2 784 (49.1%)  
 1-2 years 287 (7.9%) 743 (13.1%)  
Sex % Male 2 128 (58.6%) 3 409 (60.1%) 0.133 
Category Admitted to specialist PICUa 2 980 (82.0%) 3 652 (64.4%) <0.001 
 Interhospital transport 1 667 (45.9%) 2 209 (39.0%) <0.001 
Risk category Prematurity 747 (20.6%) 950 (16.8%) <0.001 
 Chronic Lung Disease  229 (6.3%) 224 (4.0%) <0.001 
 Other chronic respiratory disease 117 (3.2%) 200 (3.5%) 0.425 
 Congenital heart disease 281 (7.7%) 330 (5.8%) <0.001 
 Chronic neurological disease 77 (2.1%) 107 (1.9%) 0.433 
 any comorbidity 1 328 (36.5%) 1 640 (28.9%) <0.001 
Etiology RSV 1624 (44.7%) 2039 (36.0%) <0.001 
 Influenza 61 (1.7%) 84 (1.5%) 0.454 
 Human Metapneumovirus 0 (0.0%) 120 (2.1%) <0.001 
 Parainfluenzavirus 67 (1.8%) 115 (2.0%) 0.531 
 Adenovirus 41 (1.1%) 192 (3.4%) <0.001 
Severity Mean PICU Length of Stay (SD)  [days] 3.69 (5.82) 3.18 (4.33) <0.001 
 Mean Hospital Length of Stay (SD) 12.47 (36.21) 9.13 (23.79) <0.001 
 PIM2 (mean probability of death) (SD) 0.96% (1.7%) 0.69% (1.9%) <0.001 
 
Median PICU Length of Stay (IQR)  
[days] 
2.29 (1.08-
4.46) 
2.25 (1.33-
3.75) 
0.623 
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 Median Hospital Length of Stay (IQR) 
6.93 (4.33-
11.47) 
5.05 (3.43-
8.25) 
<0.001 
 
PIM2 (median probability of death) 
(IQR) 
0.59% (0.21-
1.00%) 
0.27% (0.18-
0.77%) 
<0.001 
 Death  25 (0.7%) 10 (0.2%) <0.001 
 
 
aSpecialist Pediatric Intensive Care Unit (versus general ICU) 
PICU, Pediatric Intensive Care Unit; PIM2, Paediatric Index of Mortality-2.
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Table 2: Population-based admission rate of bronchiolitis 2002-2014 (per 100,000 infants <24 months) 
 
Sites 
Total ICU  
admissions due to 
respiratory infection 
Bronchiolitis admissions  
rate per 100,000 population <24 months (n) 
Proportion of  
admitted patients 
Year PICU General All PICU All PICU General 13-year* 
General/All 
(n/n %) All PICU 
2002 9 6 589 549 62.5 (383) 58.5 (358) 4.1 (25) 62.0 (380) 6.5% 19.8% 19.5% 
2003 9 7 575 508 51.9 (317) 43.6 (266) 8.4 (51) 49.3 (301) 16.1% 16.7% 15.3% 
2004 9 7 629 583 59.4 (366) 55.0 (339) 4.4 (27) 58.1 (358) 7.4% 17.2% 17.0% 
2005 9 7 640 568 60.7 (380) 52.4 (328) 8.3 (52) 56.5 (354) 13.7% 19.4% 18.1% 
2006 9 8 780 637 82.7 (531) 66.5 (427) 16.2 (104) 72.0 (462) 19.6% 24.3% 22.2% 
2007 9 12 824 641 78.3 (529) 59.7 (403) 18.7 (126) 62.2 (420) 23.8% 22.3% 19.9% 
2008 9 13 921 747 82.5 (579) 63.5 (446) 18.9 (133) 64.2 (451) 23.0% 23.3% 21.1% 
2009 9 15 891 712 76.8 (549) 57.8 (413) 19.0 (136) 62.0 (443) 24.8% 22.9% 20.0% 
2010 9 15 1,083 811 106.5 (766) 76.5 (550) 30.0 (216) 78.8 (567) 28.2% 26.7% 23.3% 
2011 9 15 1,308 897 123.5 (880) 80.0 (570) 43.5 (310) 85.5 (609) 35.2% 27.8% 23.0% 
2012 9 17 1,606 1,098 167.0 (1206) 108.0 (780) 59.0 (426) 114.5 (827) 35.3% 34.4% 29.0% 
2013 9 19 1,739 1,189 174.5 (1290) 112.9 (835) 61.5 (455) 120.0 (887) 35.3% 33.6% 28.3% 
2014 10** 19 1,969 1,265 208.9 (1528) 125.3 (917) 83.5 (611) 138.3 (1012) 40.0% 37.1% 30.7% 
  
β 
(95% CI) 
113.65 
(86.99-
140.32) 
61.36 
(46.65-76.1) 
11.84 (8.24 το 
15.45) 
5.83 (3.75 το 
7.91) 
6.01 (4.37 το 
7.65) 
6.25 (3.86 το 
8.63) 
0.03 (0.02 το 
0.03) 
0.02 (0.01 to 
0.02) 
0.01 (0.01 to 
0.01) 
  
p 
(for 
trend) 
<0.0001 <0.0001 
<0.0001 0.0001 <0.0001 0.0001 <0.0001 <0.0001 <0.0001 
• dataset restricted to units that had been contributing data to the registry for the entire study period 2002-2014 
** Two PICUs that had contributed data to the registry since 2002 merged at the end of 2014 to one new facility. 
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Table 3: Multivariate model to prediction of likelihood of requiring intubation and invasive ventilation in critically ill infants 
with bronchiolitis. Data are based on a saturated mix-effects logistic regression model clustering on site and adjusted for all 
variables shown in the table. 
 
Odds 
Ratio (95% CI) β (95% CI) p 
Age (Days/30) 0.970 (0.957 to 0.983) -0.013 (-0.044 to -0.017) <0.001 
Interhospital transport 2.718 (2.415 to 3.058) 0.434 (0.882 to 1.118) <0.001 
Chronic Neurological Condition 1.723 (1.187 to 2.502) 0.236 (0.171 to 0.917) 0.004 
Chronic Respiratory Condition 1.585 (1.182 to 2.124) 0.200 (0.167 to 0.753) 0.002 
Bronchopulmonary Dysplasia 1.686 (1.324 to 2.148) 0.227 (0.280 to 0.765) <0.001 
Congenital Heart Defect 1.875 (1.536 to 2.289) 0.273 (0.429 to 0.828) <0.001 
Prematurity  1.320 (1.147 to 1.520) 0.121 (0.137 to 0.419) <0.001 
RSV 1.561 (1.387 to 1.757) 0.193 (0.327 to 0.564) <0.001 
Influenza/Parainfluenzae 2.001 (1.523 to 2.629) 0.301 (0.421 to 0.967) <0.001 
Systolic blood pressure <=70 4.034 (3.160 to 5.151) 0.606 (1.151 to 1.639) <0.001 
Base Excess 0.947 (0.929 to 0.967) -0.023 (-0.074 to -0.034) <0.001 
(Base Excess)^2 1.010 (1.008 to 1.013) 0.004 (0.008 to 0.012) <0.001 
Constant 0.087 (0.063 to 0.121) -1.060 (-2.768 to -2.113) <0.001 
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Online Supplementary Material: 
Burden of Disease and Change in Practice in Critically Ill Infants with Bronchiolitis in Australia and New Zealand 2002 to 2014 
 
Luregn J Schlapbach
1,2,3*
, Lahn Straney
4*
, Ben Gelbart
5,6
, Janet Alexander
7,8
, Donna Franklin
1
, John Beca
9
, Jennifer A. Whitty
10,11
, Subodh Ganu
12,13
, Barry Wilkins
14
, Elizabeth 
Croston
15
, Simon Erickson
15
, Andreas Schibler
1,2 
on behalf of the Australian & New Zealand Intensive Care Society (ANZICS) Centre for Outcomes & Resource Evaluation (CORE) and the Australian & New Zealand Intensive 
Care Society (ANZICS) Paediatric Study Group 
 
 
Methods 
 
ANZPIC Registry. The ANZPIC Registry was created in 1997 and prospectively records demographics, physiologic variables at admission, intensive care support, diagnoses and 
outcomes of PICU and general ICU admissions in children <16 years of age in Australia and New Zealand. The registry captures 92-94% of all pediatric ICU admissions. Data 
are entered by trained ICU data collectors, and funding is provided by state governments in Australia and New Zealand. Data validation and auditing of PICUs and larger general 
ICUs are performed biennially.  
Population-based admission rate estimates: Age-specific population data were accessed through the Australian Bureau of Statistics 
(http://www.abs.gov.au/AUSSTATS/abs@.nsf/second+level+view?ReadForm&prodno=3101.0&viewtitle=Australian%20Demographic%20Statistics~Jun%202012~Previous~1
8/12/2012&&tabname=Past%20Future%20Issues&prodno=3101.0&issue=Jun%202012&num=&view=&) and through Statistics New Zealand 
(http://www.stats.govt.nz/estimates-projections). 
The diagnosis of bronchiolitis was based on the prospective diagnostic coding used in each patient in the ANZPIC Registry, including the principal diagnosis, the underlying 
diagnosis, or any of the associated diagnoses. The coding is based on the ICU discharge diagnosis by the ICU physicians. 
 
Comorbidity definitions: The following comorbidities were defined to characterize patients with underlying disease: prematurity (< 37 weeks gestational age), chronic lung 
disease, underlying chronic respiratory disease other than prematurity-related chronic lung disease, congenital heart disease, chronic neurologic disease (encephalopathy; chronic 
central or peripheral nervous system disease), and other comorbidities (including renal disease, immunodeficiency or immunosuppression, haematological or solid organ tumors, 
status post bone marrow transplantation, and solid organ transplant recipients).  
 
Cost estimates: 
The ANZPIC registry data were used to estimate the costs of bronchiolitis in Australia and New Zealand, using 2014 Australian dollar costings.  The costing model applied 
standardised prices from the National Efficient Price Determination (2014/2015) 
(https://www.ihpa.gov.au/sites/g/files/net636/f/publications/national_efficient_price_determination_2014-15.pdf). This model presents the activity based funding that would be 
provided by the Commonwealth to hospitals, based on an assumed Australian Refined Diagnosis – Related Group of Bronchiolitis with complications (E70A), weighted for time 
spent in intensive care, length of hospital stay and/or paediatric service. For the years 2003-2014 if data for hospital LOS were missing, imputation was used based on the median 
LOS for that corresponding year for general or paediatric ICU settings. As there were limited hospital LOS data available for 2002, the median LOS for 2003 was imputed for 
2002.   
 
Statistics and risk prediction models: 
To assess change in risk-adjusted mortality, we recalibrated PIM2 among these patients using the linear prediction of the PIM2 model in a logistic regression model. Population-
based admission rate estimates were calculated. We assessed linear trends in respiratory support over the 13-year period. In addition, trends during the 13-year study period were 
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assessed by comparing risk-adjusted need for invasive ventilation. We constructed a multivariate prediction model for the need for invasive ventilation. For multivariable models, 
all significant predictors from the univariable analyses were used. We used a backward stepwise elimination procedure to eliminate non-significant predictors based on p>0.05.  
For risk prediction models, we ran a saturated mix-effects logistic regression model clustering on site. The variance of the random effect was used as a measure of unit-level 
variation. To avoid spurious associations between predictors that were correlated with time, we ran the saturated model with the year of admission. The model building process 
was undertaken using backward elimination of the covariate with the highest p-value. We selected the final model based on the lowest Akaike information criterion (AIC)
1
. The 
final model excluded year of admission from the model to calculate risk-adjusted change over time. A risk score for each child was calculated using the fixed effects portion of 
the model and the mean was calculated to estimate the average risk score of intubation. Unit level variability was reported using the predicted probability of intubation in each 
site for a child with the mean risk score and the site-specific random effect.  
 
 
Acknowledgements 
We thank the Paediatric Study Group of the Australian and New Zealand Intensive Care Society for supporting this study (Simon Erickson, Princess Margaret Hospital for 
Children, Perth, Australia; Andreas Schibler, Anthony Slater, Debbie Long, Jan Alexander, Lady Cilento Children’s Hospital, Brisbane, Australia; John Beca, Claire Sherring, 
Starship Children’s Hospital, Auckland, New Zealand; Gary Williams, Janelle Young, Mary Lou Morritt, Sydney Children’s Hospital, Randwick, Australia; Johnny Millar, 
Carmen Del Zoppo, Warwick Butt, Royal Children’s Hospital, Melbourne, Australia; Subodh Ganu, Georgia Letton, Women’s and Children’s Hospital, Adelaide, Australia; 
Marino Festa, Westmead Children’s Hospital, Sydney, Australia). We thank the intensivists, data managers and other staff in the participating ICUs for their data contributions. 
The ANZPIC Registry is supported by the Australian and New Zealand Intensive Care Society, the Ministry of Health (New Zealand), and State and Territory Health 
Departments through the Australian Health Ministers’ Advisory Council 
 
 
  
Page 31 of 45 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 3
Online Supplement Figure 1: Kaplan-Meyer curves comparing time to intubation (in hours) from PICU admission in infants with bronchiolitis admitted to PICU. Only 
infants that were not intubated during the first hour of admission were included. 
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Online Supplement Table 1: Respiratory support mode and duration of respiratory support in infants with bronchiolitis admitted to ICU per year are shown for A) all 
ICU admissions captured in the Australian and New Zealand Paediatric Intensive Care Registry; B) admissions to Pediatric Intensive Care Units (PICUs); C) 
admissions to general Intensive Care Units (ICUs); D) admissions to PICUs and ICUs that had contributed to the registry for the entire study duration 2002-2014. 
Mechanical ventilation is defined as intubation and/or non-invasive ventilation. HFNC, High-Flow Nasal Cannulae. 
 
Online Supplement Table 1 A: All ICUs 
 
Proportion of respiratory support Mean duration of respiratory support (hours)* 
Year 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
All respiratory  
support 
2002 57.2% 36.6% 30.5% 108.6 125.5 53.1 62.1 
2003 53.9% 30.9% 35.0% 84.1 105.1 36.7 45.4 
2004 57.4% 29.2% 42.6% 102.7 147.2 37.2 58.9 
2005 56.8% 29.5% 42.4% 93.9 112.4 47.8 53.4 
2006 60.5% 26.9% 47.5% 94.1 134.7 43.4 56.9 
2007 62.8% 26.5% 49.7% 88.0 126.1 44.0 55.3 
2008 53.2% 23.5% 40.9% 87.2 119.9 44.6 46.4 
2009 63.4% 25.9% 46.8% 84.7 125.7 45.3 53.7 
2010 58.6% 24.5% 42.2% 24.7% 76.7 95.8 50.9 44.3 55.9 
2011 62.0% 16.6% 59.3% 35.8% 68.8 109.3 41.4 35.5 55.4 
2012 58.1% 20.1% 44.7% 54.7% 70.8 98.7 47.8 37.1 61.5 
2013 46.6% 12.6% 38.5% 71.2% 55.6 84.1 39.8 31.6 48.4 
2014 44.8% 10.8% 38.2% 72.6% 69.2 122.3 46.6 35.3 56.6 
β  
(95% CI) 
-0.01  
(-0.01 to 0.00) 
-0.02  
(-0.02 to -0.01) 
0.01  
(-0.01 to 0.02) 
0.06  
(0.04 to 0.09) 
-3.40  
(-4.56 to -2.25) 
-2.23  
(-4.77 to 0.30) 
0.09  
(-0.75 to 0.92) 
-2.19  
(-5.82 to 1.44) 
-0.03  
(-0.92 to 0.86) 
p  
(trend) 
0.2311 <0.0001 0.2787 0.0001 <0.0001 0.0789 0.8260 0.1503 0.9472 
* Among those children receiving this mode of respiratory support 
** Defined as intubation and/or non-invasive ventilation 
HFNC, High-Flow Nasal Cannulae 
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Online Supplement Table 1 B: PICU 
 
Proportion of respiratory support Mean duration of respiratory support (hours)* 
Year 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
All respiratory  
support 
2002 56.7% 37.2% 29.6% 109.8 125.2 53.1 62.3 
2003 54.1% 32.3% 33.8% 88.0 105.7 39.8 47.6 
2004 58.1% 30.4% 42.5% 106.0 148.2 39.0 61.6 
2005 65.2% 34.1% 48.5% 94.6 112.4 48.2 61.7 
2006 58.1% 31.1% 42.6% 105.0 137.5 42.6 61.0 
2007 64.5% 29.3% 51.1% 94.2 129.0 45.0 60.8 
2008 56.1% 25.1% 44.8% 90.8 126.6 42.6 50.9 
2009 64.9% 27.6% 47.7% 91.2 131.2 48.1 59.2 
2010 58.9% 29.6% 38.7% 30.7% 80.4 101.4 44.7 41.4 60.1 
2011 58.8% 19.3% 55.4% 48.2% 83.3 120.8 46.3 35.3 66.0 
2012 52.4% 21.4% 39.2% 62.1% 80.1 105.2 49.6 40.6 67.2 
2013 45.5% 13.7% 37.0% 76.0% 63.9 92.0 44.6 32.1 53.4 
2014 46.3% 13.0% 39.4% 74.9% 84.5 135.1 55.0 35.9 66.1 
β  
(95% CI) 
-0.01  
(-0.02 to 0.00) 
-0.02  
(-0.02 to -0.01) 
0.00  
(-0.01 to 0.02) 
0.07  
(0.04 to 0.10) 
-2.54  
(-3.83 to -1.24) 
-1.24  
(-3.90 to 1.42) 
0.44  
(-0.32 to 1.19) 
-1.41  
(-5.12 to 2.29) 
0.46  
(-0.49 to 1.42) 
p  
(trend) 
0.0845 0.0000 0.4860 0.0001 0.0012 0.3264 0.2296 0.3119 0.3105 
* Among those children receiving this mode of respiratory support 
** Defined as intubation and/or non-invasive ventilation 
HFNC, High-Flow Nasal Cannulae 
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Online Supplement Table 1 C: general ICUs 
 
Proportion of respiratory support Mean duration of respiratory support (hours)* 
Year 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
All respiratory  
support 
2002 64.0% 28.0% 44.0% 93.4 130.2 53.0 59.8 
2003 52.9% 23.5% 41.2% 63.3 101.5 23.5 33.5 
2004 48.1% 14.8% 44.4% 52.8 123.1 16.2 25.4 
2005 3.8% 0.0% 3.8% 17.5 0.0 17.5 0.7 
2006 70.2% 9.6% 67.3% 57.0 96.5 45.7 40.0 
2007 57.1% 17.5% 45.2% 65.9 110.7 40.5 37.6 
2008 43.6% 18.0% 27.8% 71.7 88.2 55.2 31.3 
2009 58.8% 20.6% 44.1% 63.1 103.3 35.9 37.1 
2010 57.9% 11.6% 50.9% 9.3% 67.2 59.4 62.8 68.8 45.2 
2011 68.1% 11.6% 66.5% 12.9% 45.7 74.1 33.9 36.9 35.9 
2012 68.5% 17.6% 54.7% 41.3% 57.9 84.2 45.5 27.4 51.0 
2013 48.6% 10.5% 41.3% 62.4% 41.4 65.4 32.0 30.5 39.2 
2014 42.4% 7.5% 36.3% 69.1% 44.0 89.2 32.8 34.2 42.3 
β  
(95% CI) 
0.01  
(-0.02 to 0.03) 
-0.01  
(-0.02 to 0.00) 
0.01  
(-0.02 to 0.04) 
0.05  
(0.03 to 0.08) 
-1.56  
(-4.46 to 1.34) 
-4.20  
(-6.67 to -1.72) 
0.65  
(-1.75 to 3.04) 
-7.55  
(-21.18 to 6.07) 
0.78  
(-1.54 to 3.09) 
p  
(trend) 
0.6891 0.1846 0.5180 0.0010 0.2623 0.0036 0.5634 0.1759 0.4756 
* Among those children receiving this mode of respiratory support 
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Online Supplement Table 1 D: PICUs and ICUs that had contributed to the registry for the entire study duration 2002-2014. 
Proportion of respiratory support Mean duration of respiratory support (hours)* 
Year 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
Mechanical 
Ventilation** 
Invasive 
ventilation 
Non-Invasive 
Ventilation HFNC 
All respiratory  
support 
2002 57.1% 36.6% 30.5% 109.5 126.3 53.4 62.5 
2003 55.8% 32.2% 36.2% 85.4 106.1 37.1 47.6 
2004 58.1% 29.9% 43.0% 103.5 147.2 37.5 60.2 
2005 59.9% 31.4% 44.6% 93.3 113.4 45.5 55.9 
2006 60.0% 29.0% 45.7% 96.9 136.5 40.6 58.1 
2007 64.5% 28.1% 51.7% 91.4 129.0 44.1 59.0 
2008 53.7% 23.9% 42.4% 84.2 119.2 39.4 45.2 
2009 65.9% 28.0% 48.3% 85.6 123.8 45.1 56.4 
2010 62.3% 29.8% 42.5% 28.2% 74.4 97.1 40.9 38.8 57.3 
2011 59.8% 18.1% 56.7% 42.7% 77.6 119.8 43.7 35.9 61.7 
2012 56.0% 21.3% 42.6% 57.1% 73.7 100.2 46.8 39.5 63.8 
2013 48.9% 13.4% 40.6% 75.9% 58.6 89.6 41.0 30.3 51.6 
2014 49.7% 12.8% 42.5% 75.9% 76.0 129.9 49.7 33.8 63.5 
β  
(95% CI) 
0.00  
(-0.01 to 0.00) 
-0.02  
(-0.02 to -0.01) 
0.01  
(0.00 to 0.02) 
0.07  
(0.04 to 0.09) 
-3.03  
(-4.23 to -1.83) 
-1.73  
(-4.30 to 0.85) 
0.17  
(-0.63 to 0.97) 
-1.55  
(-4.87 to 1.77) 
0.29  
(-0.69 to 1.27) 
p  
(trend) 
0.2526 0.0000 0.1868 0.0001 0.0002 0.1682 0.6524 0.2346 0.5223 
* Among those children receiving this mode of respiratory support 
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Online Supplement Table 2: Estimates of population-based intubation rates in infants with bronchiolitis admitted to ICU per year. Analyses are shown for all ICU 
admissions captured in the Australian and New Zealand Paediatric Intensive Care Registry; admissions to Pediatric Intensive Care Units (PICUs); admissions to general Intensive 
Care Units (ICUs); and admissions to PICUs and ICUs that had contributed to the registry for the entire study duration 2002-2014.  
All PICUs and ICUs PICU General ICUs 
8 PICUs and 5 ICUs contributing to 
registry for the entire study duration 
2002-2014 
Year n 
Population rate  
(per 100,000) n 
Population rate  
(per 100,000) n 
Population rate  
(per 100,000) n 
Population rate  
(per 100,000) 
2002 140 22.86 133 21.72 7 1.14 139 22.69 
2003 98 16.06 86 14.09 12 1.97 97 15.89 
2004 107 17.37 103 16.72 4 0.65 107 17.37 
2005 112 17.88 112 17.88 0 0.00 111 17.72 
2006 143 22.28 133 20.72 10 1.56 134 20.87 
2007 140 20.72 118 17.47 22 3.26 118 17.47 
2008 136 19.37 112 15.95 24 3.42 108 15.38 
2009 142 19.87 114 15.95 28 3.92 124 17.35 
2010 188 26.14 163 22.66 25 3.48 169 23.49 
2011 146 20.50 110 15.44 36 5.05 110 15.44 
2012 242 33.52 167 23.13 75 10.39 176 24.38 
2013 162 21.91 114 15.42 48 6.49 119 16.09 
2014 165 22.55 119 16.27 46 6.29 130 17.77 
β  
(95% CI) 
6.62  
(2.01 to 11.22) 
0.59  
(-0.07 to 1.24) 
1.99  
(-1.62 to 5.60) 
-0.03  
(-0.55 to 0.49) 
4.63  
(2.73 to 6.52) 
0.62  
(0.35 to 0.88) 
2.23  
(-1.53 to 5.98) 
-0.01  
(-0.55 to 0.52) 
p (trend) 0.0091 0.0732 0.2505 0.9020 0.0002 0.0004 0.2185 0.9603 
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Online Supplementary Table 3: Multivariate model to prediction of likelihood of requiring intubation and invasive ventilation in critically ill infants with bronchiolitis. 
Data are based on a saturated mix-effects logistic regression model clustering on site and adjusted for all variables shown in the table. Data are restricted to A) Infants that were 
not intubated within the first hour of ICU admission, and B) to infants treated with HFNC and not intubated during the 1
st
 hour of ICU admission: 
 
 
A) Multivariate prediction of intubation restricted to infants that were not intubated at time on ICU admission (n=8451) 
 
Odds 
Ratio (95% CI) β (95% CI) p 
Age (Days/30) 0.968 (0.953 to 0.984) -0.032 (-0.048 to -0.016) <0.001 
Interhospital transport 1.621 (1.407 to 1.868) 0.483 (0.342 to 0.625) <0.001 
Chronic Neurological Condition 1.285 (0.815 to 2.024) 0.251 (-0.204 to 0.705) 0.280 
Chronic Respiratory Condition 1.531 (1.092 to 2.146) 0.426 (0.088 to 0.764) 0.014 
Bronchopulmonary Dysplasia 2.035 (1.546 to 2.679) 0.711 (0.435 to 0.986) <0.001 
Congenital Heart Defect 2.168 (1.737 to 2.707) 0.774 (0.552 to 0.996) <0.001 
Prematurity  1.198 (1.006 to 1.427) 0.180 (0.006 to 0.355) 0.043 
RSV 1.609 (1.394 to 1.857) 0.475 (0.332 to 0.619) <0.001 
Influenza/Parainfluenzae 1.978 (1.440 to 2.718) 0.682 (0.364 to 1.000) <0.001 
Systolic blood pressure <=70 2.916 (2.145 to 3.963) 1.070 (0.763 to 1.377) <0.001 
Base Excess 0.974 (0.950 to 0.999) -0.026 (-0.052 to -0.001) 0.043 
(Base Excess)^2 1.007 (1.005 to 1.009) 0.007 (0.005 to 0.009) <0.001 
Constant 0.968 (0.953 to 0.984) -0.032 (-0.048 to -0.016) <0.001 
 
 
Model performance: ROC AUC=0.72 (0.70-0.73) 
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B) Multivariate prediction of intubation in infants not intubated on arrival and treated with High-Flow Nasal Cannulae (n=3049) 
 
Odds 
Ratio (95% CI) β (95% CI) p 
Age (Days/30) 0.935 (0.902 to 0.970) -0.067 (-0.103 to -0.031) <0.001 
Interhospital transport 0.967 (0.694 to 1.348) -0.033 (-0.365 to 0.298) 0.845 
Chronic Neurological Condition 1.054 (0.357 to 3.118) 0.053 (-1.031 to 1.137) 0.924 
Chronic Respiratory Condition 1.673 (0.846 to 3.310) 0.515 (-0.167 to 1.197) 0.139 
Bronchopulmonary Dysplasia 2.311 (1.228 to 4.349) 0.838 (0.206 to 1.470) 0.009 
Congenital Heart Defect 3.512 (2.273 to 5.425) 1.256 (0.821 to 1.691) <0.001 
Prematurity  1.438 (0.985 to 2.098) 0.363 (-0.015 to 0.741) 0.060 
RSV 1.258 (0.909 to 1.742) 0.230 (-0.096 to 0.555) 0.167 
Influenza/Parainfluenzae 1.238 (0.569 to 2.692) 0.213 (-0.563 to 0.990) 0.590 
Systolic blood pressure <=70 2.730 (1.329 to 5.609) 1.004 (0.284 to 1.724) 0.006 
Base Excess 0.914 (0.861 to 0.972) -0.089 (-0.150 to -0.029) 0.004 
(Base Excess)^2 1.006 (1.002 to 1.010) 0.006 (0.002 to 0.010) 0.008 
Constant 0.935 (0.902 to 0.970) -0.067 (-0.103 to -0.031) <0.001 
 
 
Model performance: ROC AUC=0.74 (0.70-0.77) 
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Online Supplementary Table 4: Direct hospitalization costs for infants with bronchiolitis per year. Mean costs per patient, including ICU and ward costs, are shown in 
AU$, separately for Pediatric Intensive Care Units (PICUs) versus general ICUs. Costs are based on the standardised National Efficient Price estimates. 
 
Cost per patient Total cost Summary 
 General   PICU   General   Pediatric   Total  ICU proportion   General   PICU   Total Cost 
 Year   Mean   SD   Mean   SD   ICU cost   ward cost   ICU cost   ward cost   ICU cost   ward cost   % total costs   total cost   total cost  
 2,002   24,571   15,987   29,667   32,428   450,699   177,836   7,301,624   3,370,482   7,752,323   3,548,318   68.6   628,535   10,672,106   11,300,641 
 2,003   22,613   19,560   32,012   65,878   694,072   459,174   4,773,400   3,741,913   5,467,473   4,201,087   56.5   1,153,247   8,515,313  
 2,004   19,998   12,780   32,777   39,949   331,252   208,695   6,914,274   4,197,043   7,245,527   4,405,738   62.2   539,947   11,111,318   11,651,265 
 2,005   18,477   18,041   30,479   26,460   416,145   544,662   6,124,645   3,872,461   6,540,789   4,417,124   59.7   960,807   9,997,106   10,957,913 
 2,006   26,475   30,715   42,902   133,939   1,492,448   1,260,964   9,179,501   9,139,854   10,671,949   10,400,818   50.6   2,753,411   18,319,356   21,072,767 
 2,007   23,820   20,253   39,437   61,389   1,698,067   1,303,253   8,114,717   7,778,538   9,812,784   9,081,791   51.9   3,001,320   15,893,255   18,894,575 
 2,008   29,820   34,239   33,455   52,525   1,805,356   2,160,746   8,513,158   6,407,941   10,318,514   8,568,687   54.6   3,966,102   14,921,098   18,887,201 
 2,009   23,370   25,861   37,490   85,851   1,960,210   1,218,117   8,838,224   6,645,107   10,798,435   7,863,224   57.9   3,178,327   15,483,332   18,661,659 
 2,010   19,872   11,628   36,773   56,309   2,480,658   1,811,645   10,091,138   10,133,951   12,571,796   11,945,596   51.3   4,292,303   20,225,089   24,517,392 
 2,011   20,153   16,027   33,503   38,340   3,636,948   2,610,413   11,129,047   7,967,907   14,765,994   10,578,320   58.3   6,247,360   19,096,954   25,344,314 
 2,012   24,410   38,743   34,022   62,482   6,128,484   4,270,114   14,533,286   12,003,541   20,661,770   16,273,655   55.9   10,398,598   26,536,827   36,935,425 
 2,013   22,540   23,417   25,997   30,383   5,851,196   4,404,621   13,388,088   8,319,706   19,239,284   12,724,327   60.2   10,255,817   21,707,795   31,963,612 
 2,014   21,645   29,875   33,924   81,866   7,983,325   5,241,709   17,126,139   13,982,132   25,109,464   19,223,840   56.6   13,225,034   31,108,271   44,333,304 
 
 
 
1. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1994; 19(6): 716-23. 
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Figure 1: Estimated population-based ICU admission rates due to bronchiolitis. ICU admission rates per 
100,000 infants < 24 months and year are shown for A) all ICU admissions captured in the Australian and 
New Zealand Paediatric Intensive Care Registry; B) admissions to Pediatric Intensive Care Units (PICUs); C) 
admissions to general Intensive Care Units (ICUs); D) admissions to PICUs and ICUs that had contributed to 
the registry for the entire study duration 2002-2014. Red line: age 28days to <90 days; blue line: age 
neonates <28days; green line: 90 days to <1 year; purple line: 1 year to <2 years.  
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Figure 2: Changes is respiratory support mode during the study period 2002 to 2014 in infants admitted to 
ICU with bronchiolitis. Mechanical ventilation (green line) is defined as intubation (purple line: invasive 
ventilation) and/or non-invasive ventilation (blue line). High-flow nasal cannulae (HFNC) is shown in orange. 
Proportions of respiratory support mode used per patient (more than one modality allowed) are shown for A) 
all ICU admissions captured in the Australian and New Zealand Paediatric Intensive Care Registry; B) 
admissions to Pediatric Intensive Care Units (PICUs); C) admissions to general Intensive Care Units (ICUs); 
D) admissions to PICUs and ICUs that had contributed to the registry for the entire study duration 2002-
2014.  
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Figure 3: Adjusted risk for intubation/invasive ventilation in infants with bronchiolitis during the study 
period. Odds ratios are adjusted for age, interhospital transport, chronic respiratory and neurological 
conditions, prematurity, congenital heart disease, specific respiratory viruses, low systolic blood pressure, 
and are shown for A) all ICU admissions captured in the Australian and New Zealand Paediatric Intensive 
Care Registry; B) admissions to Pediatric Intensive Care Units (PICUs); C) admissions to general Intensive 
Care Units (ICUs); D) admissions to PICUs and ICUs that had contributed to the registry for the entire study 
duration 2002-2014.  
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